Topic Hub
4 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 4 of 4 clinical reviews.
Inclisiran (Leqvio) is FDA-approved for LDL-C lowering in ASCVD patients, but its role in reducing cardiovascular events is still being defined. This guide covers trial data from ORION-10, ORION-11, and ORION-4, side effects, cost, and where inclisiran fits in the ASCVD treatment algorithm.
Read clinical reviewA clinical evidence summary of inclisiran (Leqvio) use in familial hypercholesterolemia, including FDA-approved HeFH data from ORION-9 and off-label HoFH data from ORION-5, with GRADE-level assessments and guideline context.
Read clinical reviewInclisiran (Leqvio) is FDA-approved for ASCVD, not familial hypercholesterolemia. Learn the off-label dosing protocol, ORION trial evidence, and how clinicians are using it for HeFH.
Read clinical reviewA clinician-focused review of inclisiran (Leqvio) for ASCVD secondary prevention, covering off-label status, LDL-C efficacy data from ORION trials, dosing protocol, and guideline context.
Read clinical review